Support LinksChrome Firefox Safari Edge View Versions © 2026 Advarra, Inc.

To search for a clinical trial (protocol), use any or all of the search fields: Select from drop down lists or type search criteria in any of the text fields. Browse by Physician or Drug, use the …

Inclusion Criteria Age 18 years or older;At least one measurable lesion according to RECIST v1.1 OR evaluable disease for a limited number of patients (up to 10) in Group H;Performance …

Objectives Primary Objective To evaluate the safety, feasibility, and tolerability of soft tissue ablation with the Muse MRgFUS system as assessed by subject-reported procedural pain and …

Objectives Master Protocol: Primary Objectives To identify experimental therapies that improve OS for GBM patients in the Screening stage (Stage 1), determining if predefined patient …

Objectives Primary Objective To compare overall survival in participants with newly diagnosed metastatic renal cell carcinoma who are randomized to receive immune checkpoint inhibitor …

Exclusion Criteria Exclusion Criteria: Patients are excluded from the study if any of the following criteria apply: History of prior therapy with an anti-CD19 targeting agentActive acute or chronic …

To evaluate the anti-tumor activities (RECIST-defined response rate, median PFS) and safety profiles of ipilimumab + nivolumab and dabrafenib-trametinib in a Cooperative Group trial of …

Inclusion Criteria Pre-Registration Eligibility Criteria: Patients must have pathologically confirmed pancreatic adenocarcinoma.Received 4-6 months of induction chemotherapy with either …

SIP Version 14.0.0.010 Copyright © 2001-2020 Forte Research Systems, Inc. all rights reserved.